BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:INCA33890 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of INCA33890\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06179160-2547@assetmemo.bio
DTSTAMP:20261121T005829Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:INCA33890: Phase 1 readout est. (NCT06179160)
DESCRIPTION:INCA33890\, phase 1.\nStudy: A Study to Evaluate INCB161734 in 
 Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutat
 ion\nEstimated primary completion: 1 January 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/inca33890#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06179160
URL:https://assetmemo.bio/drug/inca33890#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284849-2547@assetmemo.bio
DTSTAMP:20261121T005829Z
DTSTART;VALUE=DATE:20281229
DTEND;VALUE=DATE:20281230
SUMMARY:INCA33890: Phase 3 readout est. (NCT07284849)
DESCRIPTION:INCA33890\, phase 3\, Colorectal Cancer.\nStudy: A Study to Eva
 luate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevaciz
 umab With or Without INCA33890 in the First-Line Treatment of Metastatic M
 icrosatellite Stable Colorectal Cancer\nEstimated primary completion: 29 D
 ecember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/inca338
 90#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7284849
URL:https://assetmemo.bio/drug/inca33890#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05836324-2547@assetmemo.bio
DTSTAMP:20261121T005829Z
DTSTART;VALUE=DATE:20290503
DTEND;VALUE=DATE:20290504
SUMMARY:INCA33890: Phase 1 readout est. (NCT05836324)
DESCRIPTION:INCA33890\, phase 1.\nStudy: A Study to Evaluate the Safety of 
 INCA33890 in Participants With Advanced or Metastatic Solid Tumors\nEstima
 ted primary completion: 3 May 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/inca33890#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05836324
URL:https://assetmemo.bio/drug/inca33890#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07823322-2547@assetmemo.bio
DTSTAMP:20261121T005829Z
DTSTART;VALUE=DATE:20290514
DTEND;VALUE=DATE:20290515
SUMMARY:INCA33890: Phase 2 readout est. (NCT07823322)
DESCRIPTION:INCA33890\, phase 2\, Colorectal Cancer.\nStudy: A Study to Eva
 luate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage I
 I/III Microsatellite Stable Colorectal Cancer After Curative Resection and
  Chemotherapy\nEstimated primary completion: 14 May 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/inca33890#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07823322
URL:https://assetmemo.bio/drug/inca33890#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07876414-2547@assetmemo.bio
DTSTAMP:20261121T005829Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:INCA33890: Phase 2 readout est. (NCT07876414)
DESCRIPTION:INCA33890\, phase 2.\nStudy: A Clinical Trial Comparing an Anti
 body (INCA33890) Versus Pembrolizumab for Squamous Cell Carcinoma of the H
 ead and Neck.\nEstimated primary completion: February 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/inca33890#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07876414
URL:https://assetmemo.bio/drug/inca33890#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
